• Veea entered a term sheet to combine with NovaGen, targeting a definitive business combination agreement within weeks.
• Transaction aims to create a Nasdaq-listed longevity and precision-health platform alongside Veea’s ongoing edge AI infrastructure business.
• GeoNova Capital committed USD 10 million as a cornerstone investment in the combined company under a separate term sheet.
• Management estimates the combined company’s value at about USD 750 million, based on internal projections and an independent valuation.
• Closing remains subject to definitive documentation and satisfaction of customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veea Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-100507), on September 16, 2026, and is solely responsible for the information contained therein.